We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Danaher (DHR) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Danaher (DHR - Free Report) to post quarterly earnings of $1.62 per share in its upcoming report, which indicates a year-over-year decline of 15.6%. Revenues are expected to be $5.56 billion, down 4.2% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Danaher metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Total sales- Diagnostics' stands at $2.34 billion. The estimate indicates a change of -7.2% from the prior-year quarter.
The combined assessment of analysts suggests that 'Total sales- Life Sciences' will likely reach $1.64 billion. The estimate points to a change of -6% from the year-ago quarter.
Analysts expect 'Total sales- Biotechnology' to come in at $1.59 billion. The estimate suggests a change of +4% year over year.
Based on the collective assessment of analysts, 'Operating profit- Life Sciences' should arrive at $199.97 million. Compared to the present estimate, the company reported $235 million in the same quarter last year.
It is projected by analysts that the 'Operating profit- Biotechnology' will reach $398.00 million. Compared to the current estimate, the company reported $325 million in the same quarter of the previous year.
The collective assessment of analysts points to an estimated 'Operating profit- Diagnostics' of $585.46 million. The estimate compares to the year-ago value of $830 million.
Over the past month, shares of Danaher have returned -10.7% versus the Zacks S&P 500 composite's -4.2% change. Currently, DHR carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Danaher (DHR) Q1 Earnings, Beyond Revenue and EPS
Wall Street analysts expect Danaher (DHR - Free Report) to post quarterly earnings of $1.62 per share in its upcoming report, which indicates a year-over-year decline of 15.6%. Revenues are expected to be $5.56 billion, down 4.2% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Danaher metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Total sales- Diagnostics' stands at $2.34 billion. The estimate indicates a change of -7.2% from the prior-year quarter.
The combined assessment of analysts suggests that 'Total sales- Life Sciences' will likely reach $1.64 billion. The estimate points to a change of -6% from the year-ago quarter.
Analysts expect 'Total sales- Biotechnology' to come in at $1.59 billion. The estimate suggests a change of +4% year over year.
Based on the collective assessment of analysts, 'Operating profit- Life Sciences' should arrive at $199.97 million. Compared to the present estimate, the company reported $235 million in the same quarter last year.
It is projected by analysts that the 'Operating profit- Biotechnology' will reach $398.00 million. Compared to the current estimate, the company reported $325 million in the same quarter of the previous year.
The collective assessment of analysts points to an estimated 'Operating profit- Diagnostics' of $585.46 million. The estimate compares to the year-ago value of $830 million.
View all Key Company Metrics for Danaher here>>>
Over the past month, shares of Danaher have returned -10.7% versus the Zacks S&P 500 composite's -4.2% change. Currently, DHR carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>